- Home
- NODK vs INAB Comparison
NODK vs INAB Comparison
Compare NODK & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NODK | INAB |
|---|---|---|
| Founded | 1946 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.8M | 22.9M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NODK | INAB |
|---|---|---|
| Price | $12.48 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 17.2K | ★ 61.6K |
| Earning Date | 03-06-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $285,050,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.01 | $0.12 |
| 52 Week High | $14.70 | $4.20 |
Technical Indicators
Market Signals| Indicator | NODK | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 33.42 | 36.59 |
| Support Level | $12.34 | $1.17 |
| Resistance Level | $13.70 | $2.59 |
| Average True Range (ATR) | 0.42 | 0.21 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 0.86 | 5.26 |
Price Performance
Historical ComparisonAbout NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. Through its subsidiaries, the company operates in the insurance industry, offering homeowners and farmowners insurance policies, crop insurance policies, home insurance policies, etc. These insurance products are distributed through a network of exclusive and independent agents across the United States. The group's reportable segments are: Private Passenger Auto, Non-Standard Auto, Home and Farm, Crop, and All Other (which mainly consists of commercial, assumed reinsurance, and its excess liability business). Maximum revenue is generated from the Home and Farm segment.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.